Hepatitis Monthly

Published by: Kowsar

TM6SF2 rs58542926 Polymorphism is not Associated With Risk of Steatosis or Fibrosis in Chilean Patients With Chronic Hepatitis C

Alvaro Urzua 1 , Gabriel Mezzano 1 , Javier Brahm 1 , Jaime Poniachik 1 , Julio Miranda 1 , Dante D. Caceres 2 , Laura Carreno 3 and Mauricio Venegas 1 , *
Authors Information
1 Gastroenterology Section, Department of Medicine, University of Chile Clinical Hospital, Santiago, Chile
2 Environmental Health Program, School of Public Health, Faculty of Medicine, University of Chile
3 Department of Pathology, University of Chile Clinical Hospital, Santiago, Chile
Article information
  • Hepatitis Monthly: April 30, 2017, 17 (4); e12307
  • Published Online: April 12, 2017
  • Article Type: Brief Report
  • Received: February 7, 2017
  • Revised: March 9, 2017
  • Accepted: March 25, 2017
  • DOI: 10.5812/hepatmon.44365

To Cite: Urzua A, Mezzano G, Brahm J, Poniachik J, Miranda J, et al. TM6SF2 rs58542926 Polymorphism is not Associated With Risk of Steatosis or Fibrosis in Chilean Patients With Chronic Hepatitis C, Hepat Mon. 2017 ; 17(4):e12307. doi: 10.5812/hepatmon.44365.

Copyright © 2017, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Methods
3. Results
4. Discussion
  • 1. Cooke GS, Lemoine M, Thursz M, Gore C, Swan T, Kamarulzaman A, et al. Viral hepatitis and the Global Burden of Disease: a need to regroup. J Viral Hepat. 2013;20(9):600-1. doi: 10.1111/jvh.12123. [PubMed: 23910643].
  • 2. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57(4):1333-42. doi: 10.1002/hep.26141. [PubMed: 23172780].
  • 3. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41-52. doi: 10.1056/NEJM200107053450107. [PubMed: 11439948].
  • 4. Huang CF, Chuang WL, Yu ML. Chronic hepatitis C infection in the elderly. Kaohsiung J Med Sci. 2011;27(12):533-7. doi: 10.1016/j.kjms.2011.10.020. [PubMed: 22208535].
  • 5. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349(9055):825-32. [PubMed: 9121257].
  • 6. Wright M, Goldin R, Fabre A, Lloyd J, Thomas H, Trepo C, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut. 2003;52(4):574-9. [PubMed: 12631672].
  • 7. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology. 2008;134(6):1699-714. doi: 10.1053/j.gastro.2008.02.069. [PubMed: 18471548].
  • 8. Patin E, Kutalik Z, Guergnon J, Bibert S, Nalpas B, Jouanguy E, et al. Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. Gastroenterology. 2012;143(5):1244-52 e1-12. doi: 10.1053/j.gastro.2012.07.097. [PubMed: 22841784].
  • 9. Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, Tybjaerg-Hansen A, et al. Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2014;46(4):352-6. doi: 10.1038/ng.2901. [PubMed: 24531328].
  • 10. Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, et al. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nat Commun. 2014;5:4309. doi: 10.1038/ncomms5309. [PubMed: 24978903].
  • 11. Coppola N, Rosa Z, Cirillo G, Stanzione M, Macera M, Boemio A, et al. TM6SF2 E167K variant is associated with severe steatosis in chronic hepatitis C, regardless of PNPLA3 polymorphism. Liver Int. 2015;35(8):1959-63. doi: 10.1111/liv.12781. [PubMed: 25581573].
  • 12. Milano M, Aghemo A, Mancina RM, Fischer J, Dongiovanni P, De Nicola S, et al. Transmembrane 6 superfamily member 2 gene E167K variant impacts on steatosis and liver damage in chronic hepatitis C patients. Hepatology. 2015;62(1):111-7. doi: 10.1002/hep.27811. [PubMed: 25820484].
  • 13. Petta S, Maida M, Grimaudo S, Pipitone RM, Macaluso FS, Cabibi D, et al. TM6SF2 rs58542926 is not associated with steatosis and fibrosis in large cohort of patients with genotype 1 chronic hepatitis C. Liver Int. 2016;36(2):198-204. doi: 10.1111/liv.12918. [PubMed: 26259026].
  • 14. Thiers V, Jaffredo F, Tuveri R, Chodan N, Brechot C. Development of a simple restriction fragment length polymorphism (RFLP) based assay for HCV genotyping and comparative analysis with genotyping and serotyping tests. J Virol Methods. 1997;65(1):9-17. [PubMed: 9128857].
  • 15. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21. doi: 10.1002/hep.20701. [PubMed: 15915461].
  • 16. Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, et al. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology. 2015;61(2):506-14. doi: 10.1002/hep.27490. [PubMed: 25251399].
  • 17. Sookoian S, Castano GO, Scian R, Mallardi P, Fernandez Gianotti T, Burgueno AL, et al. Genetic variation in transmembrane 6 superfamily member 2 and the risk of nonalcoholic fatty liver disease and histological disease severity. Hepatology. 2015;61(2):515-25. doi: 10.1002/hep.27556. [PubMed: 25302781].
  • 18. Trepo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology. 2011;54(1):60-9. doi: 10.1002/hep.24350. [PubMed: 21488075].
  • 19. Petta S, Vanni E, Bugianesi E, Rosso C, Cabibi D, Camma C, et al. PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. Aliment Pharmacol Ther. 2015;41(10):939-48. doi: 10.1111/apt.13169. [PubMed: 25801076].
  • 20. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-85. doi: 10.1111/j.1365-2036.2011.04724.x. [PubMed: 21623852].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments